Continuing story · 1 report

Moderna-Merck melanoma vaccine trial

First aired Latest aired

Gone quiet since

Where it stands

On August 19, Moderna and Merck reported unpublished topline results showing their personalized vaccine plus Keytruda reduced the risk of recurrence or spread of high-risk advanced melanoma compared with Keytruda alone. The trial’s final results and follow-up have not yet been reported.

Explore with HeyDex

Story trackerDay 1

1 report11 outlets11 sources1 video

  • No dated events yet
    1. Update 1A One-Person Shot Delayed Melanoma's Return. The Proof Is Still Missing.

    The story so far

    1. Update 1

      A One-Person Shot Delayed Melanoma's Return. The Proof Is Still Missing.

      Merck and Moderna say their personalized mRNA plus Keytruda met two recurrence endpoints in high-risk melanoma — but with no numbers, no safety data and no paper, scale and approval remain unproven.

      Still open after this report

      • No magnitude of benefit, hazard ratios, absolute risk reduction, overall survival, durability, safety details, cost, turnaround time, or FDA review timeline is established on this record.
      • The exact enrollment number and the size and durability of the market move at a single agreed timepoint are not established.

    History

    1. Opened1 report

    Who's involved

    Places

    • United StatesUnited States1 report

    Every outlet we read on this story

    11 sources11 outlets1 video